First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

By sjmartinez • October 28, 2022

Hamid O, Chiappori AA, Thompson JA, Doi T, Hu-Lieskovan S, Eskens FALM, Ros W, Diab A, Spano JP, Rizvi NA, Wasser JS, Angevin E, Ott PA, Forgie A, Yang W, Guo C, Chou J, El-Khoueiry AB. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. J Immunother Cancer. 2022 Oct;10(10):e005471. doi: 10.1136/jitc-2022-005471. PMID: 36302562.

Tags: Combination, drug therapy, Hematology/Oncology, Immunomodulation, immunotherapy, Investigational, Publications, Therapies

Tumor-Specific EphA2 Receptor Tyrosine Kinase Inhibits Anti-Tumor Immunity by Recruiting Suppressive Myeloid Populations in Murine Models of Non-Small Cell Lung Cancer

Shiuan E, Wang S, Brantley-Sieders DM. Tumor-Specific EphA2 Receptor Tyrosine Kinase Inhibits Anti-Tumor Immunity by Recruiting Suppressive Myeloid Populations in Murine Models of Non-Small Cell[...]

Prediction of Early Neoadjuvant Chemotherapy Response of Breast Cancer through Deep Learning-based Pharmacokinetic Quantification of DCE MRI

Wu C, Wang L, Wang N, Shiao S, Dou T, Hsu YC, Christodoulou AG, Xie Y, Li D. Prediction of Early Neoadjuvant Chemotherapy Response of[...]

Addressing the Unmet Need for Treatment in Advanced Hepatocellular Carcinoma With Child-Pugh C Cirrhosis: A Case of a Woman With Hepatocellular Carcinoma and Advanced Liver Disease

Chamberlain E, Cleveland JM. Addressing the Unmet Need for Treatment in Advanced Hepatocellular Carcinoma With Child-Pugh C Cirrhosis: A Case of a Woman With Hepatocellular[...]